This article stated that Caduet is covered by three US patents US 4,681,893 (which covers atorvastatin calcium); 5,273,995 (which covers amlodipine besylate); and 6,455,574 (which covers the product). In fact, both the '893 and the '995 patents relate to atorvastatin calcium.
Additional information
The online version of the original article can be found at 10.1038/nrd2516
Rights and permissions
About this article
Cite this article
Harrison, C. Erratum: Ranbaxy loses in Caduet dispute. Nat Rev Drug Discov 7, 458 (2008). https://doi.org/10.1038/nrd2569
Issue Date:
DOI: https://doi.org/10.1038/nrd2569
